Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

February 25, 2020

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

 FLORHAM PARK, NJ.–Feb. 25, 2020– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief Executive Officer, and Azmi Nabulsi, M.D., Chief Operating Officer, will present at Cowen and Company’s 40th Annual Healthcare Conference in Boston on March 2, 12:00 pm EST at the Boston Marriott Copley Place.

To access the live webcast and archived recordings for this presentation, visit the Investors & Media section of the Phathom Pharmaceuticals website at www.phathompharma.com.

 

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at www.phathompharma.com.

Follow Phathom on LinkedIn at www.linkedin.com/company/phathompharma.

 

Media Contacts:

Joe Hand
1-877-742-8466

info@phathompharma.com

Nick Benedetto

1-877-742-8466

media@phathompharma.com

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

patti.bank@westwicke.com